June 6, 2019 10:05 AM EDT

Financially wobbly opioid drugmaker Insys agrees to pay $225M to settle government probes

Natalie Grover

Reporter

After being found guilty of engaging in a bribery scheme to get doctors to prescribe its potent, addictive painkiller and duping insurers into paying for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Financially wobbly opioid drugmaker Insys agrees to pay $225M to settle government probes

Natalie Grover

Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Fi­nan­cial­ly wob­bly opi­oid drug­mak­er In­sys agrees to pay $225M to set­tle gov­ern­ment probes

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Financially wobbly opioid drugmaker Insys agrees to pay $225M to settle government probes